Amgen Plans $1 Billion Manufacturing Expansion in North Carolina
In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
"This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world," said Robert A. Bradway, Amgen’s CEO. "North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact."
Combined with the existing facility, the investment will create 370 new jobs in the region, supporting the company’s biomanufacturing hub.
Amgen's selection reflects North Carolina's position as a premier life sciences destination with a vibrant innovation ecosystem and skilled workforce, the company said.
© Amgen
